Vor Biopharma (VOR) Competitors

Stoke Therapeutics (NASDAQ:STOK) and Vor Biopharma (NASDAQ:VOR) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, media sentiment, institutional ownership and profitability.

Is STOK or VOR more profitable?

Stoke Therapeutics has a net margin of 26.25% compared to Vor Biopharma's net margin of 0.00%. Stoke Therapeutics' return on equity of 18.32% beat Vor Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stoke Therapeutics	26.25%	18.32%	15.48%
Vor Biopharma	N/A	N/A	N/A

Do insiders and institutionals have more ownership in STOK or VOR?

97.3% of Vor Biopharma shares are held by institutional investors. 9.5% of Stoke Therapeutics shares are held by insiders. Comparatively, 0.5% of Vor Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Does the media prefer STOK or VOR?

In the previous week, Stoke Therapeutics had 19 more articles in the media than Vor Biopharma. MarketBeat recorded 20 mentions for Stoke Therapeutics and 1 mentions for Vor Biopharma. Vor Biopharma's average media sentiment score of 1.77 beat Stoke Therapeutics' score of 0.66 indicating that Vor Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Stoke Therapeutics	7 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Vor Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Do analysts rate STOK or VOR?

Stoke Therapeutics presently has a consensus price target of $25.57, suggesting a potential upside of 30.73%. Given Stoke Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Stoke Therapeutics is more favorable than Vor Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stoke Therapeutics	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.22
Vor Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Which has stronger earnings and valuation, STOK or VOR?

Vor Biopharma has lower revenue, but higher earnings than Stoke Therapeutics. Vor Biopharma is trading at a lower price-to-earnings ratio than Stoke Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stoke Therapeutics	$36.56M	29.32	-$88.98M	$0.85	23.01
Vor Biopharma	N/A	N/A	N/A	-$13.66	-0.16

Which has more risk and volatility, STOK or VOR?

Stoke Therapeutics has a beta of 1.15, indicating that its stock price is 15% more volatile than the S&P 500. Comparatively, Vor Biopharma has a beta of 2.06, indicating that its stock price is 106% more volatile than the S&P 500.

Summary

Stoke Therapeutics beats Vor Biopharma on 12 of the 15 factors compared between the two stocks.